We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.
To save content items to your account,
please confirm that you agree to abide by our usage policies.
If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account.
Find out more about saving content to .
To save content items to your Kindle, first ensure coreplatform@cambridge.org
is added to your Approved Personal Document E-mail List under your Personal Document Settings
on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part
of your Kindle email address below.
Find out more about saving to your Kindle.
Note you can select to save to either the @free.kindle.com or @kindle.com variations.
‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi.
‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.
Plasmodium falciparum is the most severe form of malaria and is responsible for most of the neurological complications. The erythrocyte stages of P. falciparum are responsible for the acute symptoms and probably the development of epilepsy. The manifestations of severe P. falciparum malaria include coma, seizures, severe anemia, metabolic acidosis, and, in nonimmune individuals, renal impairment and pulmonary edema. Complex partial seizures are infrequently reported from the African children, but this may be caused by difficulties in describing the semiology in this patient group. Most patients who develop epilepsy following severe malaria respond to first-line antiepileptic drugs (AEDs), such as phenobarbital, phenytoin, and carbamazepine, used in resource-poor countries. The epilepsy following malaria is often associated with considerable comorbidity, particularly behavioral and neurocognitive impairment in children. The aminoquinolones, such as chloroquine and mefloquine, are contraindicated in patients with epilepsy, based upon a number of case reports.